切换至 "中华医学电子期刊资源库"

中华老年骨科与康复电子杂志 ›› 2020, Vol. 06 ›› Issue (01) : 56 -61. doi: 10.3877/cma.j.issn.2096-0263.2020.01.011

所属专题: 文献

Meta分析

长链非编码RNA TUG1在骨肉瘤中的发生机制—系统回顾和荟萃分析
孙红1, 喻乔2, 毛谷平3, 杨鹏4, 吴信1, 宁旭1, 杨华1,()   
  1. 1. 550004 贵阳,贵州医科大学附属医院骨科
    2. 550018 贵阳,贵黔国际总医院骨科
    3. 510080 广州,中山大学附属第一医院关节外科
    4. 550004 贵阳,贵州医科大学临床医学院
  • 收稿日期:2019-06-09 出版日期:2020-02-05
  • 通信作者: 杨华
  • 基金资助:
    贵州省卫生计生委基金项目(gzwjkj2017-1-031)

The role and prognostic value of long noncoding RNA TUG1 in human osteosarcoma: A systematic review and meta-analysis

Hong Sun1, Qiao Yu2, Guping Mao3, Peng Yang4, Xin Wu1, Xu Ning1, Hua Yang1,()   

  1. 1. Department of Orthopaedics, Affiliated Hospital of Guizhou Medical University Guiyang 550004, China
    2. International General Hospital of Guiqian, Guiyang 550018, China
    3. Department of Joint Surgery, The First Affiliated Hospital of Sun Yat-sen University
    4. Department of Clinical Medical College, Guizhou Medical University Guiyang 550004, China
  • Received:2019-06-09 Published:2020-02-05
  • Corresponding author: Hua Yang
引用本文:

孙红, 喻乔, 毛谷平, 杨鹏, 吴信, 宁旭, 杨华. 长链非编码RNA TUG1在骨肉瘤中的发生机制—系统回顾和荟萃分析[J/OL]. 中华老年骨科与康复电子杂志, 2020, 06(01): 56-61.

Hong Sun, Qiao Yu, Guping Mao, Peng Yang, Xin Wu, Xu Ning, Hua Yang. The role and prognostic value of long noncoding RNA TUG1 in human osteosarcoma: A systematic review and meta-analysis[J/OL]. Chinese Journal of Geriatric Orthopaedics and Rehabilitation(Electronic Edition), 2020, 06(01): 56-61.

目的

本研究旨在系统回顾长链非编码RNA TUG1(lncRNA TUG1)在骨肉瘤发生、发展中的机制,以及探讨TUG1在评估骨肉瘤患者预后中的价值。

方法

系统检索PubMed、Embase、Web of Science、CochraneLibrary、中国知网(CNKI)和万方医学数据库,收集TUG1与骨肉瘤发生及预后的相关文献。系统回顾TUG1在骨肉瘤发生、发展中的机制,并采用Stata12软件(Stata公司,美国)对TUG1与骨肉瘤患者预后的相关性进行meta分析。

结果

目前的研究表明,TUG1主要通过发挥竞争性内源RNA(competing endogenous RNA)效应调控骨肉瘤细胞增殖、凋亡和侵袭等过程,涉及通路包括AKT信号通路和Wnt/β-catenin信号通路。本研究共纳入4篇文献进行meta分析,共244例骨肉瘤患者。TUG1表达升高的骨肉瘤患者总体生存率低于TUG1表达降低的骨肉瘤患者(OR=1.921,95% CI:1.361,2.712,P=0.000)。不仅如此,骨肉瘤患者组织中TUG1表达升高往往提示肿瘤具有更大的体积(OR=4.084,95% CI:2.313,7.211,P=0.000)、较高的临床分级(OR=0.247,95% CI:0.133,0.539,P=0.000)和更早期远处转移(OR=1.943,95% CI:1.130,3.339,P=0.016)。然而,其与患者性别(OR=1.055,95% CI:0.620,1.793,P=0.844)和肿瘤发生部位(OR=0.806,95% CI:0.424,1.530,P=0.509)无显著相关性。

结论

长链非编码RNATUG1与骨肉瘤发生、发展密切相关。不仅如此,TUG1表达升高提示骨肉瘤患者不良临床预后,其可能是一种评估骨肉瘤患者预后的生物学标志物。

Objective

This study aimed toinvestigate the underlying mechanisms, and the prognostic value of long non coding RNA taurine-upregulated gene 1 (lncRNA, TUG1)inthe development and progression of osteosarcoma.

Methods

PubMed, Embase, Web of Science, Cochrane Library, ChinaNational Knowledge Internet (CNKI) and Wanfang database were systematically searched for the relevant literature of TUG1 in the development and prognosis of osteosarcoma. STATA12 (Stata Corp, College Station, Texas) was used to estimate pooled effects and the heterogeneity among studies.

Results

Current studies indicated that TUG1 regulates the proliferation, apoptosis, and invasion by acting as a ceRNA. The underlying mechanisms include AKT and Wnt/β-catenin signal pathways. Four records with a total of 244 osteosarcoma patients were enrolled in this study. The pooled results showed that the patients with high TUG1 expression had shorter overall survival (OS) compared to the patients with low TUG1 expression (OR=1.921, 95% CI: 1.361, 2.712, P=0.000). Moreover, elevated TUG1 expression was associated with advanced tumor size (OR=4.084, 95% CI: 2.313, 7.211, P=0.000), clinical stage (OR=0.258, 95%CI: 0.098, 0.682, P=0.006), and early distant metastasis (OR=1.943, 95% CI: 1.130, 3.339, P=0.016). Nevertheless, high TUG1 expression was not related to gender (OR=1.055, 95% CI: 0.620, 1.793, P=0.844) and anatomical dislocation (OR=0.806, 95% CI: 0.424, 1.530, P=0.509).

Conclusions

LncRNA TUG1 plays an important role in the molecular mechanisms of osteosarcoma. Elevated TUG1 expression indicates poor OS and clinical parameters in patients undergoing osteosarcoma, which may be used as a moderate prognostic biomarker in human osteosarcoma.

表1 meta分析文献临床特征
图1 文献筛选流程图
表2 TUG1在骨肉瘤中的发生、发展中的作用
图2~3 TUG1表达与骨肉瘤患者OS相关性的森林图及漏斗图
表3 TUG1表达升高与临床病理特征相关性meta分析结果
1
Rickel K, Fang F, Tao JN. Molecular genetics of osteosarcoma [J]. Bone, 2017, 102(SI): 69-79.
2
Miller BJ, Gao YB, Duchman KR. Socioeconomic measures influence survival in osteosarcoma: an analysis of the National Cancer Data Base [J]. Cancer Epidemiol, 2017, 49(8): 112-117.
3
Smolle MA, Pichler M. The Role of Long Non-Coding RNAs in Osteosarcoma[J]. Noncoding RNA, 2018,4(1):7.
4
孙红,张志奇,傅明. 长链非编码RNA在骨关节炎与骨肿瘤领域的研究进展 [J]. 中国骨与关节杂志, 2016, 5(5): 397-400.
5
Li JP, Liu LH, Li J, et al. Microarray expression profile of long noncoding RNAs in human osteosarcoma [J]. Biochem Biophys Res Commun, 2013, 433(2): 200-206.
6
Zhang Q, Geng PL, Yin P, et al. Down-regulation of long non-coding RNA TUG1 inhibits osteosarcoma cell proliferation and promotes apoptosis [J]. Asian Pac J Cancer Prev, 2013, 14(4): 2311-2315.
7
Wang HP, Yu YZ, Fan SX, et al. Knockdown of long noncoding RNA TUG1 inhibits the proliferation and cellular invasion of osteosarcoma cells by sponging miR-153 [J]. Oncol Res, 2018, 26(5): 665-673.
8
Wang Y, Yang T, Zhang Z, et al. Long non-coding RNA TUG1 promotes migration and invasion by acting as a ceRNA of miR-335-5p in osteosarcoma cells [J]. Cancer Sci, 2017, 108(5): 859-867.
9
Li G, Liu KY, Du XH. Long Non-Coding RNA TUG1 promotes proliferation and inhibits apoptosis of osteosarcoma cells by sponging miR-132-3p and upregulating SOX4 expression [J]. Yonsei Med J, 2018, 59(2): 226-235.
10
Young TL, Matsuda T, Cepko CL. The noncoding RNA taurine upregulated gene 1 is required for differentiation of the murine retina [J]. Curr Biol, 2005, 15(6): 501-512.
11
Wang QL, Chen Q. Role of taurine upregulated gene 1 as a predictor of poor outcome in osteosarcoma [J]. J Cancer Res Ther, 2018, 14(2): S405-S409.
12
Ma B, Li M, Zhang L, et al. Upregulation of long non-coding RNA TUG1 correlates with poor prognosis and disease status in osteosarcoma [J]. Tumor Biology, 2016, 37(4): 4445-4455.
13
Yu X, Hu L, Li SY, et al. Long non-coding RNA Taurine upregulated gene 1 promotes osteosarcoma cell metastasis by mediating HIF-1 alpha via miR-143-5p [J]. Cell Death Dis, 2019, 10(4): 280.
14
Hu TZ, Fei ZH, Su HF, et al. Polydatin inhibits proliferation and promotes apoptosis of doxorubicin-resistant osteosarcoma through LncRNA TUG1 mediated suppression of Akt signaling [J]. Toxicol Appl Pharmacol, 2019, 371(5): 55-62.
15
Han XF, Yang YM, Sun YJ, et al. LncRNA TUG1 affects cell viability by regulating glycolysis in osteosarcoma cells [J]. Gene, 2018, 674(10): 87-92.
16
Xie CH, Chen B, Wu B, et al. LncRNA TUG1 promotes cell proliferation and suppresses apoptosis in osteosarcoma by regulating miR-212-3p/FOXA1 axis [J]. Biomed Pharmacother, 2018, 97(1): 1645-1653.
17
Cao JQ, Han XY, Qi X, et al. TUG1 promotes osteosarcoma tumorigenesis by upregulating EZH2 expression via mild-144-3p [J]. Int J Oncol, 2017, 51(4): 1115-1123.
18
Yang GH, Zhang C, Wang N, et al. miR-425-5p decreases LncRNA MALAT1 and TUG1 expressions and suppresses tumorigenesis in osteosarcoma via Wnt/beta-catenin signaling pathway [J]. Int J Biochem Cell Biol, 2019, 111(6): 42-51.
19
Li Y, Zhang T, Zhang YH, et al. Targeting the FOXM1-regulated long noncoding RNA TUG1 in osteosarcoma [J]. Cancer Sci, 2018, 109(10): 3093-3104.
20
Feng YB, Xiao-Po L, Xiao-Li L, et al. LncRNA TUG1 is upregulated and promotes cell proliferation in osteosarcoma [J]. Open Med, 2016, 11(1): 163-167.
21
Xie CH, Cao YM, Huang Y, et al. Long non-coding RNA TUG1 contributes to tumorigenesis of human osteosarcoma by sponging miR-9-5p and regulating POU2F1 expression [J]. Tumor Biology, 2016, 37(11): 15031-15041.
22
Li H, Tian GF, Tian FP, et al. Long non-coding RNA TUG1 promotes osteosarcoma cell proliferation and invasion through inhibition of microRNA-212-3p expression [J]. Exp Ther Med, 2018, 16(2): 779-787.
23
Quinn JJ, Chang HY. Unique features of long non-coding RNA biogenesis and function [J]. Nat Rev Genet, 2016, 17(1): 47-62.
24
Fatica A, Bozzoni I. Long non-coding RNAs: new players in cell differentiation and development [J]. Nat Rev Genet, 2014, 15(1): 7-21.
25
Bolha L, Ravnik-Glavac M, Glavac D. Long noncoding RNAs as biomarkers in cancer [J]. Dis Markers, 2017,5: 7243968.
26
Smolle MA, Pichler M. The Role of Long Non-Coding RNAs in Osteosarcoma[J]. Noncoding RNA, 2018,4(1):7.
[1] 许杰, 李亚俊, 韩军伟. 两种入路下腹腔镜根治性全胃切除术治疗超重胃癌的效果比较[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 19-22.
[2] 高杰红, 黎平平, 齐婧, 代引海. ETFA和CD34在乳腺癌中的表达及与临床病理参数和预后的关系研究[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 64-67.
[3] 李代勤, 刘佩杰. 动态增强磁共振评估中晚期低位直肠癌同步放化疗后疗效及预后的价值[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 100-103.
[4] 梁孟杰, 朱欢欢, 王行舟, 江航, 艾世超, 孙锋, 宋鹏, 王萌, 刘颂, 夏雪峰, 杜峻峰, 傅双, 陆晓峰, 沈晓菲, 管文贤. 联合免疫治疗的胃癌转化治疗患者预后及术后并发症分析[J/OL]. 中华普外科手术学杂志(电子版), 2024, 18(06): 619-623.
[5] 张志兆, 王睿, 郜苹苹, 王成方, 王成, 齐晓伟. DNMT3B与乳腺癌预后的关系及其生物学机制[J/OL]. 中华普外科手术学杂志(电子版), 2024, 18(06): 624-629.
[6] 马振威, 宋润夫, 王兵. ERCP胆道内支架与骑跨十二指肠乳头支架置入治疗不可切除肝门部胆管癌疗效的Meta分析[J/OL]. 中华肝脏外科手术学电子杂志, 2024, 13(06): 807-812.
[7] 关小玲, 周文营, 陈洪平. PTAAR在乙肝相关慢加急性肝衰竭患者短期预后中的预测价值[J/OL]. 中华肝脏外科手术学电子杂志, 2024, 13(06): 841-845.
[8] 张润锦, 阳盼, 林燕斯, 刘尊龙, 刘建平, 金小岩. EB病毒相关胆管癌伴多发转移一例及国内文献复习[J/OL]. 中华肝脏外科手术学电子杂志, 2024, 13(06): 865-869.
[9] 陈晓鹏, 王佳妮, 练庆海, 杨九妹. 肝细胞癌VOPP1表达及其与预后的关系[J/OL]. 中华肝脏外科手术学电子杂志, 2024, 13(06): 876-882.
[10] 董佳, 王坤, 张莉. 预后营养指数结合免疫球蛋白、血糖及甲胎蛋白对HBV 相关慢加急性肝衰竭患者治疗后预后不良的预测价值[J/OL]. 中华消化病与影像杂志(电子版), 2024, 14(06): 555-559.
[11] 刘郁, 段绍斌, 丁志翔, 史志涛. miR-34a-5p 在结肠癌患者的表达及其与临床特征及预后的相关性研究[J/OL]. 中华消化病与影像杂志(电子版), 2024, 14(06): 485-490.
[12] 陈倩倩, 袁晨, 刘基, 尹婷婷. 多层螺旋CT 参数、癌胚抗原、错配修复基因及病理指标对结直肠癌预后的影响[J/OL]. 中华消化病与影像杂志(电子版), 2024, 14(06): 507-511.
[13] 王景明, 王磊, 许小多, 邢文强, 张兆岩, 黄伟敏. 腰椎椎旁肌的研究进展[J/OL]. 中华临床医师杂志(电子版), 2024, 18(09): 846-852.
[14] 谭瑞义. 小细胞骨肉瘤诊断及治疗研究现状与进展[J/OL]. 中华临床医师杂志(电子版), 2024, 18(08): 781-784.
[15] 郭曌蓉, 王歆光, 刘毅强, 何英剑, 王立泽, 杨飏, 汪星, 曹威, 谷重山, 范铁, 李金锋, 范照青. 不同亚型乳腺叶状肿瘤的临床病理特征及预后危险因素分析[J/OL]. 中华临床医师杂志(电子版), 2024, 18(06): 524-532.
阅读次数
全文


摘要